Novomics develops cancer treatment-linked diagnosis systems based on its expertise and knowledge in the field of molecular diagnosis. A significant strength of Novomics is its network of specialists and clinicians, as well as the knowledge gains made possible by technological advancements in the age of precision medicine. By embracing cutting-edge clinical, molecular biological, and academic achievements and forming close collaborative relationships with pharmaceutical companies and hospitals that are significant players in the medical industry.

Part of The Mcclay Foundation, Almac Diagnostic Services Ltd. is a company headquartered in Craigavon, UK. The firm engages in development of cancer diagnostics.\nThe company says this about itself: Almac Diagnostics is a stratified medicine company specialising in biomarker driven clinical trials. The company, based in Craigavon, UK and Durham, USA has been in existence for over 15 years. Our diagnostic experience spans: Oncology, Immunology, CNS and Infective diseases.

University Health Network (UHN) is a healthcare and medical research organization in Toronto, Ontario, Canada. It is the largest such research organization in Canada and North America, ranking first in Canada for total research funding. It was named Canada's top research hospital by Research Infosource in 2015, 2016 and 2017. It was created in 1986 by the Government of Ontario through the merger of four major hospitals: Toronto General Hospital, Toronto Western Hospital, with the Princess Margaret Cancer Centre, and the Toronto Rehabilitation Institute merged in with The Toronto Hospital in 1999 and the name changed to the University Health Network. All four hospitals are affiliated with the Faculty of Medicine at the University of Toronto and serve as teaching hospitals for resident physicians, nurses, and other healthcare professions. UHN also operates The Michener Institute, an applied health sciences college that opened in 1958.

Decipher Biosciences, Inc. is a commercial-stage precision oncology company which engages in patient care improvement. The Company’s differentiated approach measures the biological activity of a patient’s entire tumor genome, known as whole transcriptome analysis, and applies proprietary machine learning algorithms to improve therapy selection and accelerate adoption of new therapies into the standard of care. Its novel prostate cancer genomic testing products examine the underlying biology of a patient’s tumor, enabling physicians to select an optimal therapy. The firm’s whole transcriptome analysis of clinical patient samples from its commercial channel and its participation in practice-changing clinical trials has allowed it to build and expand its Decipher GRID database GRID. The company was founded by Elai Davicioni, Timothy J. Triche, Bruce A. Schmidt, and Jonathan D. Buckley and is headquartered in San Diego, CA.

Taiho Pharmaceutical Co., Ltd. is engaged in the research, development, production, distribution, and marketing of pharmaceutical products. The company develops drugs primarily in the area of oncology. It also develops other pharmaceuticals, controlled medical devices, designated quasi-drugs, second-class OTC drugs, designated second-class OTC drugs, and third-class OTC drugs; S-1 for the treatment of gastric cancer; TAS-102 for the treatment of colorectal cancer; and anticancer agents for oncologists, other medical care professionals, and patients. In addition, it engages in the research and development in the areas of oncology,

Part of BioNTech SE, BioNTech Diagnostics GmbH is a company headquartered in Mainz, Germany, specializing in commercial physical and biological research. The firm was founded in 2009. Sierk P��tting is the current CEO of the company.\nThe company says this about itself: BioNTech Diagnostics is a fully-owned subsidiary company of BioNTech AG. The ISO 9001/13485 certified company has extensive product and service offerings ranging from biomarker discovery and validation through molecular screening assays, patient stratification and companion diagnostics to clinical monitoring, all to international regulatory standards. Early detection of diseases that have a high mortality rate and the appropriate selection of therapies are crucial for a successful treatment of patients. BioNTech Diagnostics�� mission is to provide new and innovative diagnostic tests to extend lives of patients, improve their quality of life and support the use of appropriate therapy for each individual patient.

PFS Genomics, Inc. provides radiation therapy for breast cancer treatment. The company was founded by Lori J. Pierce, Felix Y. Feng and Corey W. Speers and is headquartered in Vancouver, Canada.

Abbott Molecular is an emerging leader in molecular diagnostics and the analysis of DNA, RNA, and proteins at the molecular level. They are committed to exploring new clinical frontiers through the development and delivery of system and assay solutions that are designed to provide earlier disease diagnosis, selection of appropriate therapies and monitoring of disease recurrence. Their expanding portfolio brings multiples technologies that enable fast, accurate results. Their state of the art research and manufacturing facilities have hundreds of scientists who are dedicated to producing quality and reliable products. Over 350 products are available in the areas of infectious disease, oncology, genetics, and automation. Some of these products include: the m2000 system which has an extensive assay menu in infectious disease featuring Abbott RealTime technology with a broad range of assays, PathVysion HER-2 DNA Probe Kit for breast cancer, ALK Break Apart FISH Probe Kit, and UroVysion Bladder Cancer Kit are important applications of the FISH technology.

Biocrates is a developer of a metabolomics platform designed to support the discovery and validation of biomarkers for complex diseases. The company's metabolomics platform comprises an automated sample preparation workflow integrated with sensitive mass-spectrometric methods and software that controls sample management, data collection, and analysis to identify hundreds of metabolites, enabling physicians to acquire comprehensive metabolic information quickly and reliably.

Med BioGene Inc. (MBI) is a life science company based in Vancouver, British Columbia, that is currently focused on managing the license and rights to GeneFx® Lung (formerly, LungExpress Dx), a proprietary gene expression-based test for early-stage non-small-cell lung cancer. GeneFx Lung is expected to provide better-informed and personalized treatment decisions to assist in the selection of patients for adjuvant chemotherapy. MBI has partnered with Precision Therapeutics for the global commercialization of GeneFx Lung. MBI's common shares are traded on the TSX Venture Exchange.

Sysmex Corp. engages in the healthcare business. It develops, manufactures, sells, exports, and imports diagnostic instruments, reagents. and software used in in-vitro diagnostics. It also provides clinical laboratory testing of blood, urine, and other specimens. Its products include instruments and reagents diagnostics for hemostasis, immunochemistry, clinical chemistry, urinalysis, and point-of-care (POC) testing. It operates through the following geographical segments: Japan, Americas, Europe, Middle East, and Africa (EMEA), China, and Asia Pacific. The company was founded by Taro Nakatani on February 20, 1968 and is headquartered in Kobe, Japan.

Suzhou Institute of Traditional Chinese Medicine Co., Ltd., established on 1991-10-24, The scope of business includes research and development of medical Chinese herbal medicines,food,Health Supplies,medical supplies,cosmetic,Edible produce,Chinese herbal ingredients,water quality,medical instruments,Environmental and Occupational Hygiene Inspection and Testing;Biological product technology development,technical consulting,Technical Services,technology transfer.(Operations involving licenses or special approvals based on licenses or special approval documents)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) licensed items:Production of hygiene products and single-use medical products;Health food production(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Healthy food(prepackaged)Sales;Sales of hygiene products and single-use medical products;internet sales(Except for products that require a license for sale);Disinfectant sales(Free of Hazardous Chemicals);Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Pangaea Oncology SA provides molecular diagnostics and research development services in the field of personalized cancer treatment. Its research programs include biomarker discovery, molecular diagnostics assays and drug development. The firm offers tests that can detect genetic alterations that drive tumour growth in all types of cancer. The company was founded by Jose Maestre, Santiago Ramon y Cajal, Rafael Rosell and Javier Rivela in 2006 and is headquartered in Barcelona, Spain.

Jiangsu Suda Investment Co., Ltd., established on 2001-02-26, Business scope includes industrial investment,asset management,Enterprise merger and assets reorganization planning;Domestic Trade;Sales:Non-hazardous household chemicals,computer software,Laser information technology products.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

The Kyungpook National University Hospital is located in Daegu, South Korea. It was derived from the DaeGuDongIn Hospital which had opened in 1907. It has played as centered hospital of Gyeongsangbuk-do. As 1952 Kyungpook National University is established, it is following to the Kyungpook National University Hospitals. It is known to Korean as important general hospitals.